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Role of nutritional status and intervention in
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S Cox1,5, C Powell1,5, B Carter2,5, C Hurt3, Somnath Mukherjee*,4,6 and Thomas David Lewis Crosby1,6
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University of Oxford, Level 2 Admin, Churchill Hospital, Oxford OX3 7LE, UK
Background: Malnutrition is common in oesophageal cancer. We aimed to identify nutritional prognostic factors and survival
outcomes associated with nutritional intervention in the SCOPE1 (Study of Chemoradiotherapy in OesoPhageal Cancer with or
without Erbitux) trial.
Methods: Two hundred and fifty eight patients were randomly allocated to definitive chemoradiotherapy (dCRT) þ /
cetuximab. Nutritional Risk Index (NRI) scores were calculated; NRIo100 identified patients at risk of malnutrition. Nutritional
intervention included dietary advice, oral supplementation or major intervention (enteral feeding/tube placement). Univariable
and multivariable analyses using Cox proportional hazard modelling were conducted.
Results: At baseline NRIo100 strongly predicted for reduced overall survival (hazard ratio (HR) 12.45, 95% CI 5.24–29.57;
Po0.001). Nutritional intervention improved survival if provided at baseline (dietary advice (HR 0.12, P¼ 0.004), oral
supplementation (HR 0.13, Po0.001) or major intervention (HR 0.13, P¼ 0.003)), but not if provided later in the treatment
course. Cetuximab patients receiving major nutritional intervention had worse outcomes compared with controls (13 vs 28
months, P¼ 0.003).
Conclusions: Pre-treatment assessment and correction of malnutrition may improve survival outcomes in oesophageal cancer
patients treated with dCRT. Nutritional Risk Index is a simple and objective screening tool to identify patients at risk of
malnutrition.
Oesophageal cancer is the eighth most common cancer worldwide
with a 5-year survival rate of o20% (Cancer Research UK, 2016).
Malnutrition affects up to 80% of the patients and is multifactorial
in aetiology (Riccardi and Allen, 1991). Patients often present late
with obstructive symptoms, cachexia, weight loss due to locally
advanced disease. The psychological impact of diagnosis can result
in low mood and depression, which may further reduce appetite
(Van Cutsem and Arends, 2005).
Definitive chemoradiotherapy (dCRT) is a treatment option for
localised oesophageal cancer, particularly in squamous cell
carcinoma or in patients with adenocarcinoma deemed unsuitable
for surgery (Herskovic et al, 1992; Smith et al, 1998; Cooper et al,
1999; Minsky et al, 2002; Bedenne et al, 2007; Crosby et al, 2013).
Nearly half of the patients experience grade 3–4 gastrointestinal
toxicities during dCRT (Crosby et al, 2013) and 20% may require
invasive nutritional support (Gwynne et al, 2011). Nutritional
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intervention improves weight gain, performance status, tolerability
of treatment, overall survival (OS) and quality of life in oncology
patients (Lee et al, 2016). However prospective studies specifically
evaluating the impact of malnutrition and nutritional intervention
in patients with oesophageal cancer treated with dCRT are lacking.
The SCOPE1 (Study of Chemoradiotherapy in OesoPhageal
Cancer with or without Erbitux) trial was a randomised controlled
phase II/III trial comparing cisplatin-capecitabine-based dCRT for
oesophageal cancer with or without cetuximab (Crosby et al, 2013).
Two hundred and fifty eight patients were recruited from 36
centres in the UK between February 2008 and January 2012; the
trial was stopped at the phase II stage because it met criteria for
futility. The study reported an OS detriment in the cetuximab
arm (22.1 months (95% CI 15.1–24.5) vs 25.4 months (95% CI
20.5–37.9); adjusted HR 1.53 (95% CI 1.03–2.27); P¼ 0.035).
The aim of this study was to identify nutritional prognostic
factors and the survival outcome of nutritional interventions in
patients recruited to SCOPE1. We hypothesised that poor
nutritional status at baseline would be associated with worse
outcomes and nutritional intervention may improve survival.
MATERIALS AND METHODS
Study design. Patients were randomised in a 1 : 1 allocation
ratio. The control arm received four cycles of chemotherapy
with cisplatin (60mgm 2 IV day 1 of 21) and capecitabine
(625mgm 2 po bd, continuously). Concurrent conformal radio-
therapy (50Gy in 25 fractions over 5 weeks, 2 Gy per fraction)
started with cycle 3 (week 7). In the research arm, cetuximab was
commenced with cycle 1 (400mgm 2 day 1 of week 1, then
250mgm 2 weekly thereafter for 11 weeks).
The full trial protocol has been published elsewhere and was
approved by the UK Medicines and Healthcare Products
Regulatory Agency and a multicentre research ethics committee
(Hurt et al, 2011). The SCOPE1 trial was an International Standard
Randomised Controlled Trial, number 47718479. Written
informed consent was obtained from all recruited patients.
Data collection. Data on the following nutritional parameters
were prospectively collected at two time points, baseline and prior
to dCRT (week 7): albumin (g l 1), body mass index (BMI, weight
(kg) per height2 (metres)), Mellow score for dysphagia (grade 0–4)
(Mellow and Pinkas, 1985), performance status (0–1) and
nutritional intervention received (none, dietary advice, oral
supplements or major intervention). Major intervention was
defined as enteral feeding via nasogastric/nasojejunal tube place-
ment, percutaneous endoscopic gastrostomy (PEG) or
jejunostomy.
Due to difficulties in ascertaining usual body weight in cancer
patients, the Lorentz formula was used to calculate ideal body
weight (Bouillanne et al, 2005). Percentage weight loss was defined
as ((current body weight ideal body weight)/ideal body
weight) 100. The nutritional risk index (NRI) was calculated at
each time point using the following formula: NRI¼ (1.519
albumin g dl 1) þ 41.7(present weight/ideal weight) (Buzby et al,
1988; The Veterans Affairs Total Parenteral Nutrition Cooperative
Study Group, 1991; Aziz et al, 2011). Patients were stratified
according to the risk of malnutrition: NRI score X100: no risk;
NRI 97.5–100: mild risk; NRI 83.5–97.5: moderate risk; NRIo83.5:
major risk.
Cross tabulations of median survival were generated for all
effect modifiers and compared independently with the NRI and
study design stratification variables (treatment as allocated, centre,
type of tumour, stage, reason for non-surgical therapy, age, gender,
baseline weight and dysphagia score).
Statistical analysis. The main analysis determined the effect
modifiers of survival using a multivariable model at baseline.
Cox proportion hazards regression was used to model survival. As
trial participants were recruited from 36 centres, treatment centre
was included as a frailty to adjust for clustering.
The baseline Cox proportion hazards model included variables
consistent with the main trial analysis as a priori prognostic
variables (centre, disease stage, reason for no surgery, tumour type
(adenocarcinoma vs squamous histology), tumour stage, trial arm,
performance status, sex, tumour length, radiation dose, cisplatin
dose, capecitabine dose and age group). Additional justified effect
modifiers (including biochemistry and nutritional parameters)
were tested for inclusion in the base model. The main effects of
these modifiers and the pre-specified interactions were sequentially
introduced in order of statistical importance using a likelihood
ratio test (Pp0.01) independently for each time point (baseline
and pre-dCRT). Parameter estimates, standard errors and P values
were calculated. The proportional hazards assumption was assessed
visually using Kaplan-Meier plots. Non-parametric log-rank tests
were used to assess differences in hazard functions across
subgroups.
RESULTS
Data from 258 patients recruited to the SCOPE1 trial were
evaluated; details of the main analysis are published elsewhere
(Crosby et al, 2013). The median length of follow-up was 25.0 (IQR
12.6-42.7) months. The number of patients in each NRI group at
baseline was balanced between the two treatment arms (dCRT
alone vs dCRT plus cetuximab, data not shown).
The majority of patients were classified not at risk of
malnutrition (NRIX100) at baseline (217 (84%) patients); 14
(5%) were at mild risk (NRI 97.5–100), 22 (9%) at moderate risk
(NRI 83.5–97.5) and only 5 (2%) were calculated to be at major
risk (NRIo83.5). However, after 6 weeks of induction chemother-
apy the number of patients at moderate/major malnutrition risk
had increased (179 patients (70%), no risk; 16 (6%), mild risk; 48
(19%), moderate risk; 11 (4%), major risk).
The number of patients receiving nutritional intervention
increased during induction chemotherapy (143 (56%) patients at
baseline vs 192 (75%) patients prior to dCRT). Although the
number of patients receiving dietary advice alone remained
approximately stable (44 (17%) vs 40 (16%) patients), the use of
oral supplements (74 (29%) vs 110 (43%) patients) and feeding
tubes increased on treatment (25 (10%) vs 42 (16%) patients).
Median OS for patients according to NRI score and nutritional
intervention received at baseline and prior to dCRT are shown in
Tables 1 and 2. Tumour length (6–8 cm), stage III disease and
Table 1. Median survival time (months) according to
maximum nutritional intervention received and nutritional
risk index (NRI) score at baseline
NRI score
X100
(N)
497.5
(N)
o97.5
(N)
All patients
(N)a
None 34.5 (105) 7.4 (3) 3.5 (6) 29.2 (114)
Dietary advice 31.6 (39) 28.8 (2) 18.4 (3) 28.9 (44)
Oral supplements 24.6 (58) 23.9 (5) 19.1 (11) 23.4 (74)
Major nutritional intervention 24.7 (15) 44.0 (4) 10.6 (6) 23.6 (25)
All patients 27.9 (217) 21.1 (14) 11.3 (21) 24.9 (257)
aData on nutritional intervention received at baseline were missing for one patient.
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receiving o50Gy radiotherapy were identified as independent
prognostic factors in multivariable analysis (Po0.01), (Table 3).
Overall survival was significantly worse in patients classified to
be at the risk of malnutrition at baseline (NRIo100, median
survival time 15.7 months; IQR 7.4–25.8) compared with patients
not at risk (NRIX100, median survival time 31.6 months; IQR
14.7–58.0) (HR 12.5 (95% CI 5.2–29.6), Po0.001) (Figure 1). In
these at-risk patients, providing nutritional intervention at baseline
was associated with an improved OS (dietary advice (HR 0.12
(0.03–0.51), P¼ 0.004), oral supplements (HR 0.13, (0.04–0.39),
Po0.001) and major intervention (HR 0.13 (0.03–0.50), P¼ 0.003)
(Table 3; Figure 2). Univariable main effects not included in the
multivariable model are shown in Supplementary Table S1.
The median survival for patients with NRIo100 and NRIX100
prior to starting dCRT was 15.4 and 30.3 months, respectively, but
after adjustment for other factors this was not significant in the
multivariable model (HR 1.79 (0.64–5.04), P¼ 0.27, full model not
shown). Furthermore, nutritional intervention provided to at-risk
patients after the commencement of induction chemotherapy was
no longer associated with a survival benefit (dietary advice alone
HR 1.31, P¼ 0.72; oral supplements HR 0.86, P¼ 0.81; major
intervention HR 0.84, P¼ 0.81).
The only survival difference based on nutritional parameters
between the trial arms was seen in patients who required major
nutritional intervention; those allocated to dCRT plus cetuximab
had a shorter OS than those treated with dCRT alone at both
baseline (HR 4.7 (1.4–15.70), P¼ 0.01) and pre-dCRT (HR 5.4
(1.75–16.36), P¼ 0.003).
DISCUSSION
This study suggests that increased nutritional risk at baseline is
associated with reduced survival in patients with localised
oesophageal cancer treated with dCRT. An NRI score o100
strongly predicted for reduced OS. An improvement in survival
was observed following baseline nutritional intervention with
dietary advice, oral supplementation or major intervention.
A similar benefit was not observed if nutritional intervention
occurred later in the treatment course.
To our knowledge this is the first evaluation of prospectively
collected data to demonstrate the benefit of nutritional interven-
tion in oesophageal cancer. Other groups have identified
prognostic nutritional factors in patients treated with dCRT.
Thomas et al (2004) performed recursive partitioning analysis of
pre-treatment variables in 416 patients; only pre-treatment weight
loss 410% in the 6 months prior to treatment was identified as a
significant factor. BMI418 kgm 2, Atkinson dysphagia scoreo2,
dose of RT450Gy and complete response to CRT were found to
be independent prognostic factors for survival in a retrospective
analysis of 105 patients (Di Fiore et al, 2007). In a more recent
study by the same group, OS was 25 months in patients with
persistent malnutrition compared with 42 months in those who
remained well nourished during CRT (Di Fiore et al, 2014). There
is also evidence for nutritional factors as predictors of benefit
following dCRT. Di Fiore et al (2007) found a significant difference
in baseline percentage weight loss, albumin level and BMI between
responders and non-responders; response rates to dCRT were
significantly lower in patients with malnutrition at baseline and
during treatment.
Malnutrition in patients treated for oesophageal cancer is
common and may be related to the disease or its treatment
(Muscaritoli et al, 2011). Appropriate nutritional support is
important for maintaining treatment intensity and may influence
outcome (Lee et al, 2016). A formalised nutritional pathway for
patients receiving dCRT significantly reduced complications with
less weight loss, fewer unplanned hospital admissions and greater
radiotherapy completion rates observed (Odelli et al, 2005).
Concerns regarding the use of PEG feeding tubes in oesophageal
cancer relating to safety of dilatation and potential for inoculation
metastasis have been raised (Singh and Gelrud, 2015). However in
a retrospective analysis, PEG placement was successful in the
majority of patients prior to multimodality treatment for
oesophageal cancer and was significantly related to attainment of
target doses of chemoradiotherapy (P¼ 0.034), and survival at 12
months (P¼ 0.02) (Margolis et al, 2003). In our study, patients
with NRIX100 at baseline requiring major nutritional intervention
had a worse outcome than those who required no nutritional
support (24.7 vs 34.5 months, Table 1). This may represent patients
with significant dysphagia at presentation due to more locally
advanced disease and subsequent reduced survival rates. For
patients with mild (NRI 97.5–100) or moderate/major (NRIo97.5)
risk, major nutritional intervention improved survival (7.4 vs 44
months and 3.5 vs 10.6 months, respectively, Table 1).
Patients allocated to cetuximab arm who required a major
nutritional intervention at baseline had worse survival rates
compared with controls (13.3 vs 28 months); a similar finding
was observed if nutritional intervention occurred prior to dCRT
(13.3 vs 31.1 months). The cause for this survival difference is
unclear and based on small patient numbers, however, one
hypothesis is that fewer patients receiving cetuximab completed
the standard protocol treatment, with significant differences in the
number of chemotherapy cycles received and total radiotherapy
dose delivered (Crosby et al, 2013).
Our study has limitations; first, only 16% of the patients were
deemed at risk of malnutrition at baseline, which is lower than
anticipated. This may represent selection bias as only patients with
performance status 0–1 were recruited, or an inadequacy in dietetic
screening as formal dietetic assessment was not a trial prerequisite.
Second, although the nutritional data were collected prospectively,
the analysis itself is retrospective and requires further prospective
validation. Third, although data on whether patients received
nutritional intervention were collected, the details of the interven-
tion, intensity of dietetic follow-up or variation between centres
were not collected. A randomised control trial of ‘conventional
hospital protocol nutritional intervention’ vs ‘NRI-directed nutri-
tional intervention’ may be required to assess the true value of
NRI-directed intervention in this patient group.
In conclusion, assessment and correction of poor nutritional
state at baseline may be a simple and cost-effective intervention
that improves survival outcomes in oesophageal cancer patients
treated with dCRT. Nutritional Risk Index serves as a simple and
objective screening tool to identify patients at risk of malnutrition.
In this study, the benefit of nutritional intervention was no longer
observed once treatment had commenced, highlighting the need
for early nutritional assessment and intervention.
Table 2. Median survival time (months) according to
maximum nutritional intervention received and nutritional
risk index (NRI) score prior to definitive chemoradiotherapy
(dCRT)
NRI score
X100
(N)
497.5
(N)
o97.5
(N)
All patients
(N)a
None 35.7 (56) 23.1 (9) 11.3 (1) 35.1 (66)
Dietary advice 36.7 (29) 12.2 (10) 35.9 (39)
Oral supplements 24.8 (74) 19.1 (29) 11.3 (6) 23.2 (109)
Major nutritional intervention 24.7 (20) 16.5 (16) 13.0 (4) 21.4 (40)
All patients 30.2 (179) 18.3 (64) 12.5 (11) 24.9 (254)
aData on NRI score prior to dCRT were missing for four patients.
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Table 3. Univariable and multivariable analysis of baseline prognostic factors of overall survival
Survival Univariable analysis Multivariable analysis
N, median (Q3-Q1) HR, 95% CI P-value HR, 95% CI P-value
Age
o70 years 160, 26.2 (43–14.3) Reference Reference
X70 years 98, 22.6 (40.3–9.2) 1.33, (0.98–1.81) 0.068 1.19, (0.82–1.72) 0.366
Gender
Male 145, 24 (38.6–11.3) 1.47, (1.07–2.00) 0.016 1.38, (0.95–2.02) 0.095
Female 113, 26.1 (46.9–14.3) Reference Reference
Performance status
0 131, 27.2 (44–14.7) Reference Reference
1 127, 24.5 (40.3–10) 1.17, (0.86–1.59) 0.320 0.96, (0.67–1.39) 0.833
Tumour length
o2 cm 56, 30.7 (46.4–12.1) Reference Reference
2–4 cm 85, 30.3 (46.9–14.8) 1.00, (0.63–1.57) 0.992 1.16, (0.70–1.89) 0.568
4–6 cm 55, 24.9 (42.4–11.5) 1.48, (0.93–2.36) 0.102 1.40, (0.79–2.47) 0.250
6–8 cm 62, 18.2 (35.9–10) 1.87, (1.18–2.96) 0.008 1.81, (1.05–3.12) 0.034
Stage
Iþ II 103, 35.9 (46.6–15.3) Reference Reference
III 155, 23.2 (37–11.3) 1.66, (1.20–2.30) 0.002 1.58, (1.05–2.38) 0.027
Tumour type
Squamous cell 188, 25.4 (43.3–13.6) Reference Reference
Adenocarcinoma 70, 23.2 (39.1–10.2) 1.28, (0.92–1.78) 0.144 0.97, (0.62–1.52) 0.907
Reason for no surgery
Patient choice 97, 26.7 (46.6–14.7) Reference Reference
Comorbidity 36, 31.6 (42.7–11.1) 1.24, (0.79–1.94) 0.350 0.93, (0.51–1.70) 0.817
Local extent 122, 24 (40.6–11.5) 1.20, (0.86–1.69) 0.285 0.87, (0.58–1.29) 0.478
Treatment arm
dCRT only 129, 23.3 (39.4–10.2) Reference
dCRT þ cetuximab 129, 27.8 (46–14.8) 1.27, (0.94–1.71) 0.125 0.82, (0.49–1.37) 0.440
Full radiation protocol dose
Yes 217, 30.1 (46–14.9) Reference Reference
No 41, 8.2 (20.8–2.9) 3.46, (2.36–5.07) o0.001 2.92, (1.49–5.75) 0.002
% of full cisplatin protocol dose
X95% 106, 35.2 (46.9–16.9) Reference Reference
X75–o95% 76, 29 (44.3–15.3) 1.29, (0.88–1.90) 0.184 1.11, (0.70–1.75) 0.672
X50–o75% 41, 18.4 (36–12.5) 2.20, (1.44–3.38) o0.001 1.76, (1.00–3.13) 0.051
o50% 35, 10.2 (24.7–5.9) 3.17, (2.00, 5.03) o0.001 1.80, (0.86–3.76) 0.118
% of full capecitabine protocol dose
X95% 82, 32.8 (45.3–14.9) Reference Reference
X75–o95% 90, 28.1 (45.9–14.8) 1.07, (0.73–1.59) 0.719 0.99, (0.62–1.58) 0.956
X50–o75% 52, 22.5 (43.3–7.7) 1.58, (1.03–2.41) 0.035 0.97, (0.54–1.73) 0.907
o50% 34, 15.6 (23.2–5.9) 2.34, (1.46–3.76) o0.001 0.73, (0.32–1.69) 0.465
NRI
X100 217, 28 (45.9–14.2) Reference Reference
o100 41, 15.6 (24.5–8) 2.26, (1.54–3.30) o0.001 12.45, (5.24–29.6) o0.001
Nutritional intervention
None 114, 29.2 (46.8–12.8) Reference
Dietary advice alone 44, 29 (44.6–15.7) 1.05, (0.67–1.63) 0.835 1.18, (0.59–2.39) 0.638
Oral supplements 74, 23.4 (35.8–10.9) 1.49, (1.04–2.15) 0.030 1.00, (0.54–1.85) 0.992
Major intervention 25, 23.7 (40.3–10) 1.20, (0.69–2.08) 0.525 0.53, (0.19–1.50) 0.232
Nutritional intervention in the CRT þ cetuximab group
None Reference
Dietary advice alone 1.19, (0.45–3.15) 0.720
Oral supplements 1.94, (0.89–4.20) 0.093
Major intervention 4.69, (1.40–15.7) 0.012
Nutritional intervention in those with a baseline NRIo100
None Reference
Dietary advice alone 0.12, (0.03–0.51) 0.004
Oral supplements 0.13, (0.04–0.39) o0.001
Major intervention 0.13, (0.03–0.50) 0.003
Abbreviations: CI¼ confidence interval; CRT¼ chemoradiotherapy; dCRT¼definitive chemoradiotherapy; HR¼ hazard ratio; NRI¼nutritional risk index.
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